Literature DB >> 15068608

In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate.

Buck E Rogers1, Debbie Della Manna, Ahmad Safavy.   

Abstract

The goal of this study was to synthesize and evaluate a novel bombesin (BN) analogue containing a polyethylene glycol (PEG) linker that can be radiolabeled with 64Cu through the DOTA bifunctional chelate. It is hypothesized that PEG linkers would improve the pharmacokinetics of radiolabeled bombesin analogues to optimize their tumor-to-normal tissue ratios for radiotherapy applications. The formation of this conjugate (DOTA-PEG-BN(7-14)) was confirmed by MALDI-TOF mass spectrometry and was radiolabeled with 64Cu at a specific activity of 2.7 MBq/nmol. DOTA-PEG-BN(7-14) bound specifically to gastrin-releasing peptide receptor (GRPR)-positive PC-3 cells with an IC50 value of 3.9 microM for displacing 125I-Tyr4-BN. Internalization of 64Cu-DOTA-PEG-BN(7-14) into PC-3 cells showed that 5.7%, 13.4%, and 21.0% was internalized at 0.5, 2, and 4 hours, respectively. Biodistribution of 64Cu-DOTA-PEGBN(7-14) was evaluated in normal, athymic nude mice 2, 4, and 24 hours after i.v. injection. This showed that most of the tissues had a similar uptake and clearance of 64Cu-DOTA-PEG-BN(7-14) compared to a control peptide with an alkyl linker (DOTA-Aoc-BN(7-14)) at the given time points. There was uptake of 10.8% ID/g of 64Cu-DOTA-PEG-BN(7-14) 4 hours after i.v. injection in the GRPR-positive pancreas that was inhibited to 2.4% upon injection of an excess of Tyr4-BN. These studies demonstrate that BN analogues can be conjugated with PEG linkers, radiolabeled with 64Cu, and bind to GRPR. Future studies will attempt to increase the affinity of these analogues for GRPR and alter the pharmacokinetics of the 64Cu-labeled conjugates through the use of various sized PEG linkers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068608     DOI: 10.1089/108497804773391649

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  15 in total

1.  In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.

Authors:  Jeffrey M Craft; Ravindra A De Silva; Kimberly A Lears; Rebecca Andrews; Kexian Liang; Samuel Achilefu; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-01-20       Impact factor: 2.408

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 3.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

4.  Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.

Authors:  Jessie R Nedrow; Alexander G White; Jalpa Modi; Kim Nguyen; Albert J Chang; Carolyn J Anderson
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

5.  Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Authors:  Rajendra Prasad Bandari; Zongrun Jiang; Tamila Stott Reynolds; Nicole E Bernskoetter; Ashley F Szczodroski; Kurt J Bassuner; Daniel L Kirkpatrick; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; James P Connors; Charles J Smith
Journal:  Nucl Med Biol       Date:  2014-01-10       Impact factor: 2.408

6.  Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.

Authors:  Nilantha Bandara; Tamila J Stott Reynolds; Rebecca Schehr; Rajendra P Bandari; Philipp J Diebolder; Stephanie Krieger; Jingli Xu; Yubin Miao; Buck E Rogers; Charles J Smith
Journal:  Nucl Med Biol       Date:  2018-06-08       Impact factor: 2.408

7.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

8.  Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Authors:  Wojciech G Lesniak; Emilia Sikorska; Hassan Shallal; Babak Behnam Azad; Ala Lisok; Mrudula Pullambhatla; Martin G Pomper; Sridhar Nimmagadda
Journal:  Mol Pharm       Date:  2015-02-03       Impact factor: 4.939

9.  DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.

Authors:  Hanwen Zhang; Jochen Schuhmacher; Beatrice Waser; Damian Wild; Michael Eisenhut; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-30       Impact factor: 9.236

10.  Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development.

Authors:  Ravindra A De Silva; Sandeep Jain; Kimberly A Lears; Hyun-Soon Chong; Chi Soo Kang; Xiang Sun; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-06-27       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.